Inquiry Basket
Loading ......
CA 15-3 functions as a blood-based biomarker that indicates the existence of breast cancer. The MUC1 protein responsible for cell adhesion becomes overexpressed within cancerous tissues. Rising CA 15-3 levels usually suggest breast cancer but they can happen with other malignancies such as ovarian and lung cancers. CA 15-3 levels stay low during early-stage breast cancer but increase significantly with metastasis enabling this marker to monitor disease progression and treatment success. Research reveals that elevated CA 15-3 levels appear in roughly 75% of individuals diagnosed with metastatic breast cancer.
The polymorphic variable number tandem repeat (VNTR) region creates the defining structural feature of CA 15-3. The MUC1 protein encoding domain contains 60-base-pair repetitive sequences which form an N-terminal α-subunit and a C-terminal β-subunit. The mucin-like domain of the α-subunit facilitates cell-to-cell adhesion and barrier maintenance while the internal domain of the β-subunit regulates cell growth and movement by activating EGFR and Wnt signaling pathways. In normal mammary epithelial cells MUC1 is restricted to the apical membrane surface to protect mucosal barriers.
In breast cancer cells, MUC1 expression undergoes marked alterations: The DNA hypomethylation in the promoter region along with histone modifications like H3K27 trimethylation serve to boost transcriptional activity. ERα and pro-inflammatory cytokines such as TNF-α and IFN-γ activate MUC1 expression through non-canonical signaling routes at the same time. The glycosylation defects linked to tumors produce MUC1 with incomplete glycan structures which reveal CA 15-3 antigenic epitopes that are detectable in serum assays.
Figure 1. Schematic representation of MUC-1 protein
(Source: Mirabelli P, et al. 2013)
The pathway of CA 15-3 emission during disease states shows major differences from typical body functions. The membrane-bound proteases ADAM17 and MT-MMP1 cleave the MUC1 extracellular domain to release soluble CA 15-3 fragments from breast cancer cells into the bloodstream. The serum half-life of CA 15-3 exhibits dynamic variability across clinical scenarios: The serum half-life of CA 15-3 lasts about 10 days after surgical removal of the main tumor which increases to 30 days when tumor cells are destroyed by chemotherapy or radiotherapy. The liver's reticuloendothelial system primarily handles CA 15-3 clearance and liver problems such as cirrhosis or cholestasis can lead to false-positive test results. In chronic inflammatory diseases including endometriosis and tuberculosis inflammatory cytokines such as IL-6 indirectly stimulate MUC1 expression through STAT3 signaling activation which leads to reduced assay accuracy.
The normal range for CA 15-3 is generally considered to be between 0 and 30 U/mL. Exceeding this threshold may indicate breast cancer or other diseases. Interpretation of results includes: Normal levels (≤30 U/mL) typically indicate no active disease or stable condition. Elevated levels (>30 U/mL) may suggest active breast cancer, particularly in advanced stages or recurrence in previously treated patients. Elevated CA 15-3 levels can result from benign conditions like liver disease or endometriosis which means medical professionals need to interpret these results together with other diagnostic methods.
CA 15-3 proves critical in breast cancer management since it evaluates treatment success while warning doctors about tumor recurrence through chemotherapy assessments in advanced-stage patients. The AC-T treatment regimen which includes doxorubicin and cyclophosphamide followed by paclitaxel leads to greater CA 15-3 level variability than AC alone because taxanes potentially boost abnormal MUC1 release from cancer cells by disrupting microtubules. Imaging studies reveal a 70% higher chance of detecting bone or liver metastases when CA 15-3 concentrations exceed 100 U/mL. Changes in CA 15-3 levels provide early indications of treatment effectiveness or disease advancement 2–3 months before CT scans or bone scans can, which creates an important opportunity for healthcare professionals to modify patient treatment plans.
Baseline CA 15-3 levels show a strong correlation with patient survival results in prognostic evaluations. Patients who have preoperative CA 15-3 levels beyond 30 U/mL experience a 40% reduction in their 5-year disease-free survival rates versus those with standard levels because of potential micro-metastatic disease or increased tumor stem cell activity. Fluctuations in CA 15-3 during treatment also hold predictive value: Patients with CA 15-3 levels that increase by over 25% experience reduced overall survival from 14.7 months down to 6.9 months. Additionally, CA 15-3 demonstrates superior sensitivity to traditional imaging in asymptomatic recurrence monitoring. In approximately 30% of recurrence cases, CA 15-3 elevation precedes clinical symptoms by 6–8 months. Combining CA 15-3 with CEA and TPA testing increases sensitivity to 95.2%, while early intervention (e.g., switching to second-line chemotherapy or targeted therapy) can extend DFS by 8–12 months.
Figure 2. Serum CA15-3 levels in 30 different types of diseases
(Source: Li X, et al. 2019)
While CA 15-3 demonstrates significant utility in advanced breast cancer management, its low sensitivity in early-stage diagnosis remains a major limitation. The positivity rate for stage I breast cancer patients is <10%, attributed to small tumor volume, dilution of secreted CA 15-3, and efficient hepatic clearance. Strategies to address this include multimodal detection approaches: combining CA 15-3 with ultrasound elastography or mammographic calcification features can improve early diagnostic sensitivity to 65%.
False positives also pose challenges. In cirrhotic patients, portal hypertension may reduce CA 15-3 clearance via intrahepatic shunting, while inflammatory microenvironments in endometriosis lesions upregulate MUC1 expression through the IL-6/STAT3 axis, leading to nonspecific serum elevation. To mitigate these interferences, clinicians recommend establishing individualized baseline values through three consecutive measurements and using relative rate changes (e.g., >20% increase) rather than absolute values during dynamic monitoring.
Standardization of detection technologies presents another hurdle. Variations across platforms (e.g., ELISA, ECLIA, chemiluminescence) arise from differences in antibody-targeted MUC1 epitopes, particularly those binding distinct tandem repeat units of the VNTR region, resulting in poor inter-method comparability. Addressing this requires harmonizing antibody selection and establishing universal calibration protocols to enhance clinical consistency.
Table 1. Arguments for and against the use of CA 15-3 in the postoperative of patients with diagnosed breast cancer
| Arguments for using marker |
| For some women, regular measurement of CA 15-3 provides the earliest evidence of recurrent/metastatic disease. Three preliminary studies suggest that early treatment based on increasing marker levels improves outcome. Intuitively, it might be expected that the earlier treatment is commenced, the better the outcome. Availability of multiple forms of therapy for recurrent/metastatic disease. |
| Arguments against using marker |
| Lack of good (high-level) evidence that its measurement impacts on patient outcome or quality of life Low levels may provide false reassurance that patient is well. Increasing marker levels in asymptomatic women causes stress and anxiety. Marker is not elevated in all patients with recurrent/metastatic disease. (This lack of sensitivity might be minimized by measuring other markers such as CEA, TPA, TPS or HER2 extracellular domain). Markers levels may increase due to certain benign diseases. A clinically validated definition of marker increase is not available. |
(Source: Duffy MJ, et al. 2010)
Developments in epigenetic regulation methods provide new clinical opportunities for CA 15-3 usage. Clinical trials show that DNA methylation inhibitors suppress MUC1 transcription by reversing its promoter hypermethylation and display connections between decreased CA 15-3 levels and tumor shrinkage. miR-203 functions as a regulator of MUC1 expression by targeting DNA methyltransferase DNMT3b which creates a possible treatment approach for basal-like breast cancer.
Breakthroughs in nanosensor technology have significantly enhanced detection sensitivity. Electrochemiluminescence sensors based on metal-organic frameworks (MOFs), such as UiO-66-NH2-modified electrodes, achieve a detection limit as low as 1.77×10-5-100-fold more sensitive than traditional ELISA methods-while distinguishing tumor-specific glycosylated variants of MUC1. The adoption of green nanomaterials further eliminates the need for toxic reagents, laying the groundwork for point-of-care testing (POCT).
Multi-omics integration is reshaping prognostic evaluation systems for breast cancer. Deep learning models combining genomic (e.g., CDH11 hypomethylation), transcriptomic (lncRNA regulatory networks), and proteomic (CA 15-3 dynamic profiles) data enable precise stratification of patients into high/low-risk subgroups. For example, patients with CDH11 hypomethylation require CA 15-3 monitoring every 2 months, while low-risk patients can extend intervals to 6 months, optimizing healthcare resource allocation.
References
| Target | Cat. No. | Product Name | Size | Species | Application | Detection Sample | |
| CA 15-3 | DEIACL10 | CDSimple™ CA 15-3 Chemiluminescent ELISA Kit | 96T, 192T | Quantitative | Serum | Inquiry | |
| MUC1 | DEIA-BJ2496 | Mouse MUC1(Mucin-1) ELISA Kit | 96T | Mouse | Quantitative | Serum, plasma, tissue homogenates and other biological fluids. | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| CA15-3 | DAG700 | Human Breast Cancer Antigen (CA 15-3) | Human fluids | Unconjugated | ELISA, Controls | Inquiry |
| MUC1 | DAG-WT2117 | Recombinant Human MUC1 Isoform Y Protein [hFc] | HEK293 cells | hFc | Immunoassays | Inquiry |
| DAG-P0938 | Human MUC1 peptide | N/A | Unconjugated | ELISA | Inquiry | |
| DAG-P0939 | Human MUC1 peptide | N/A | Unconjugated | ELISA | Inquiry |
Loading ......
